| 摘要 |
The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 mu g/kg to 36 mu g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 mu g/kg to 36 mu g/kg of an FGF of any one of SEQ ID NOS: 1-3, 5, 8-10 or 12-14 or and angiogenically active fragment or mutein thereof. In yet another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF of any one of SEQ ID NOS: 1-3, 5, 8-10 or 12-14, or an angiogenically active fragment or mutein thereof.
|
